Exploring sex differences in endocannabinoid system biomarkers and their relationship with antidepressant treatment outcomes in major depressive disorder: a CAN-BIND 1 secondary analysis.
Maryam Sorkhou, Helena K Kim, Faranak Farzan et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial investigated sex differences in endocannabinoid system (ECS) biomarkers and their relationship with antidepressant outcomes in 178 participants with major depressive disorder (MDD). The study found that lower baseline DAGLA mRNA in males was associated with greater symptom improvement at Week 8, but no significant sex differences in ECS markers were detected after correction for multiple comparisons.
Key findings
- Baseline sex differences in methylation were noted for several genes, but none survived correction.
- Lower baseline DAGLA mRNA in males was linked to greater Week 8 symptom improvement.
- No significant associations with response or remission at Weeks 8 or 16 were found after correction.
Why it matters
Understanding sex differences in biomarkers related to antidepressant treatment could enhance personalized approaches in managing major depressive disorder. This study highlights the complexity of these relationships and the need for further research.